Frontlight ResearchEarly access
CompletedPhase 2
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 49 people enrolled
- Started
- 22 Jun 2023
- Ended
- 1 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tolcapone
- Placebo
- Record updated
- 23 September 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Men and women age 18-65 years
- Primary diagnosis of OCD
- YBOCS score of at least 21 at baseline (moderate or higher severity)
- Ability to understand and sign the consent form
Who cannot take part
- Use of any new psychotropic medication within 3 months of study entry (stable doses of psychotropics will be allowed)
- Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
- History of psychosis or bipolar disorder based on DSM-5 criteria
- Alcohol/substance use disorder and/or illegal substance use based on urine toxicology
- Major cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
- Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
- Subjects considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
- Initiation of psychological interventions within 3 months of screening (those who are continuing with CBT will be included)
- Abnormal liver function tests at baseline
- MADRS >30 at baseline
Where in United States
- University of Chicago Medical CenterChicago, United States
About the trial
What the trial wants to find out
The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
The 2 groups in the trial
- TolcaponeTreatment being tested
100mg of tolcapone twice daily for two weeks, then 200mg tolcapone twice daily for the remaining six weeks.
- PlaceboPlacebo, for comparison
100mg of placebo twice daily for two weeks, then 200mg of placebo twice daily for the remaining six weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double-Blind, Randomized, Placebo-Controlled Study of Tolcapone for OCD
- Record updated
- 23 September 2026